Bank of America
RIGL icon

Bank of America’s Rigel Pharmaceuticals RIGL Stock Holding History

Bank of America’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-22,500
Closed -$797K – 7282
2018
Q1 		$797K Buy
+22,500
New +$901K ﹤0.01% 4541

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's RIGL Position: Q1 2026 in Review

Bank of America increased its Rigel Pharmaceuticals (RIGL) stake by 23% in Q1 2026, buying an estimated $913K and bringing the position to 144,131 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3645.

Bank of America first reported a position in RIGL in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.01M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Bank of America held 144,131 shares of Rigel Pharmaceuticals worth $3.9M as of Q1 2026.
  • Bank of America bought 27,179 Rigel Pharmaceuticals shares in Q1 2026, an estimated $913K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3645 holding.
  • Bank of America first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Rigel Pharmaceuticals position peaked at $5.01M in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.